OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
तुलना करने के लिए मीट्रिक्स | OPTN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधOPTNपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −3.3x | 0.0x | −0.5x | |
PEG अनुपात | −0.09 | 0.00 | 0.00 | |
क़ीमत/बुक | −1.6x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.2x | 1.8x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | −5.5% | 95.3% | 45.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.8% | 8.6% | अनलॉक करें |